# reload+after+2024-01-23 18:43:41.042722
address1§680 West Nye Lane
address2§Suite 204
city§Carson City
state§NV
zip§89703
country§United States
phone§775 888 3162
website§https://bioviepharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
fullTimeEmployees§18
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Cuong Viet  Do M.B.A.', 'age': 57, 'title': 'President, CEO & Director', 'yearBorn': 1966, 'fiscalYear': 2023, 'totalPay': 1081500, 'exercisedValue': 0, 'unexercisedValue': 110402}, {'maxAge': 1, 'name': 'Ms. Joanne Wendy Kim CPA', 'age': 68, 'title': 'CFO, Treasurer & Corporate Secretary', 'yearBorn': 1955, 'fiscalYear': 2023, 'totalPay': 397375, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Joseph M. Palumbo M.D.', 'age': 63, 'title': 'Executive VP of R&D and Chief Medical Officer', 'yearBorn': 1960, 'fiscalYear': 2023, 'totalPay': 722000, 'exercisedValue': 0, 'unexercisedValue': 27565}, {'maxAge': 1, 'name': 'Mr. Clarence N. Ahlem', 'age': 68, 'title': 'Senior Vice President of Operations', 'yearBorn': 1955, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Penelope  Markham Ph.D.', 'age': 57, 'title': 'Senior Vice President of Liver Disease Program', 'yearBorn': 1966, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Denise  Smith', 'title': 'Senior Vice President of Manufacturing & Development', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Christopher L. Reading Ph.D.', 'age': 75, 'title': "Senior Vice President of Alzheimer's Disease Program", 'yearBorn': 1948, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sarah Overton Hoit', 'age': 56, 'title': 'Chief Social Impact Officer', 'yearBorn': 1967, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§6
compensationRisk§10
shareHolderRightsRisk§5
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.383
currency§USD
dateShortInterest§1702598400
forwardEps§-1.3
exchange§NCM
quoteType§EQUITY
shortName§BioVie Inc.
longName§BioVie Inc.
firstTradeDateEpochUtc§1600435800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§eb7eacbe-6abc-3b57-b586-2bc16fc1c3b3
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.0
targetLowPrice§5.0
targetMeanPrice§8.0
targetMedianPrice§8.0
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§2
quickRatio§1.606
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
